ArticleJournal of gastrointestinal cancer2016

Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.

Mehmet Artaç et al.PubMed ↗Publisher ↗

No numbers read from the abstract.